Abstract library

102 results for "Walter".
#1566 Splicing Dysregulation Impacts on Neuroendocrine Tumors: Evidence from Altered Spliceosoma Components and Somatostatin and Ghrelin Systems.
Introduction: Splicing is an emerging cancer hallmark influencing multiple tumor cell (dys)functions. We have shown that aberrantly spliced variants of somatostatin receptor subtype 5 (sst5TMD4) and of the pleiotropic neuropeptide ghrelin (in1ghrelin) are linked to poor prognosis in gastroenteropancreatic neuroendocrine tumors (GEPNETs) and may enhance their aggressiveness features.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Prof. Dr. Justo P. Castaño
Keywords: Splicing
#153 Antibody formation against somatostatin analogues with altered biodistribution and dosimetry: a case with implications for PRRT
Introduction: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) has emerged as a powerful palliative therapy. I.v. administration of radiolabeled (e.g. Yttrium-90) somatostatin analogues (SA) results in high-dose local irradiation of all tumor sites. The radiolabelled SA accumulates in the tumors through receptor-mediated internalization depending on the expression of somatostatin receptors and the pharmacokinetics of the radiolabelled SA.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Sofie Van Binnebeek
#67 Interest of combined chromogranin A and pancreatic polypeptide for diagnosis and follow-up of gastroenteropancreatic endocrine carcinoma
Introduction: Assessment of tumor burden changes is essential for the management of well-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEPNET). Chromogranin A (CgA) is the principal tumor marker for such tumors; however, its use to evaluate morphological tumor progression is not validated. Combined CgA and pancreatic polypeptide (PP) may increase sensitivity in the diagnosis of GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Thomas WALTER
#113 Prolonged cell survival in xenografts from human digestive endocrine tumors
Introduction: Gastroenteropancreatic endocrine tumors have the capacity to achieve very large tumor masses despite usually very low proliferative rates. This suggests that neoplastic endocrine cells may have long life spans, implying the development of specific mechanisms able to promote cell survival.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Colette Roche
#289 Gallium-68 DOTATATE PET CT Frequently Changes Patient Management or Staging When Compared with Indium-111 Octreotide in the Assessment of Neuroendocrine Tumors
Introduction: 68Ga-DOTATATE PET CT offers higher resolution than previous octreotide-labelled scintigraphic techniques, and the literature suggests increased sensitivity for the localization and staging of NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Richard W Carroll
#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas
Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
Authors: Bollard J, Couderc C, Blanc M, Poncet G, ...
#748 O6-Methylguanine-DNA Methyltransferase Deficiency in Neuroendocrine Tumors and Correlation with Response to Alkylating Agents (Temozolomide, Streptozotocin, Dacarbazine)
Introduction: Low O6-methylguanine-DNA methyltransferase (MGMT) expression is predictive of response to alkylants in some tumor types.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD thomas Walter
Keywords: MGMT
#824 Metachronous Functioning Syndromes in Sporadic Pancreatic Neuroendocrine Tumors (PNET)
Introduction: A metachronous functioning syndrome (MFS) may develop during the evolution of PNET initially functioning or not.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Louis De Mestier
Authors: De Mestier L, Hentic O, Cros J, Brixi H, ...
#956 Treatment Practices in European Centers with Interest in Neuroendocrine Carcinomas and High Grade (G3) Neuroendocrine Tumors
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ingrid Holst Olsen
#979 Characteristics and Treatments of Patients with G3 Gastroenteropancreatic Neuroendocrine Tumors (G3-NET) and Neuroendocrine Carcinoma (NEC): A European Multicenter Retrospective Study
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Maximilian Heetfeld
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.